Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Solvay Pharm BvfiledCriticalSolvay Pharm Bv
Priority to UY28470ApriorityCriticalpatent/UY28470A1/en
Publication of UY28470A1publicationCriticalpatent/UY28470A1/en
Pharmaceuticals Containing Other Organic And Inorganic Compounds
(AREA)
Abstract
La invención se refiere a una forma polimórfica estable del compuesto monometansulfonato de 7-(4-((1,1¨-bifenil)-3-ilmetil)-1-piperazinil)-2(3H)-benzoxazolona (INNM mesilato de bifeprunox), un método para la preparación de dicha forma polimórfica y su uso en productos farmacéuticos, especilamente en productos farmacéuticos para el tratamiento de desórdenes psicóticos y enfermedad de Parkinson.The invention relates to a stable polymorphic form of the monomethanesulfonate compound of 7- (4 - ((1,1¨-biphenyl) -3-ylmethyl) -1-piperazinyl) -2 (3H) -benzoxazolone (INNM bifeprunox mesylate) , a method for the preparation of said polymorphic form and its use in pharmaceutical products, specifically in pharmaceutical products for the treatment of psychotic disorders and Parkinson's disease.
UY28470A2004-08-132004-08-13
STABLE CRYSTALLINE FORM OF BIFEPRUNOX MESILATE (MONOMETANSULFONATE 7- (4- (1,1¨-BIFENIL) -3-ILMETIL) -1-PIPERAZINIL) -2- (3H) -BENZOXAZOLONA)
UY28470A1
(en)
SUBSTITUTED HETEROARILY DERIVATIVE COMPOUNDS; METHOD FOR THE PREPARATION OF COMPOUNDS; PHARMACEUTICAL COMPOSITION; AND USE FOR THE TREATMENT OF PAIN, DEPRESSION, ALZHEIMER'S DISEASE AND HYPERTENSION BETWEEN OTHERS.
NEW POLYMORPHIC FORM AND THE AMORPHY FORM OF 5- CHLORINE-N - ([(5S) -2-OXO-3- [4- (3-OXO-4-MORFOLINIL) -FENIL] -1,3-OXAZOLIDIN-5- IL] -METIL) -2-THIOPHENOCARBOXAMIDE
Compounds that are agonists of muscarinic receptors and which may be effective in the treatment of pain, Alzheimer's disease and / or schizophrenia
Crystalline form of 5- [3- (2,5-dichloro-4,6-dimethyl-1-oxy-pyridin-3-yl) - [1,2,4] oxadiazol-5-yl] -3-nitrobenzene- 1,2-diol, a pharmaceutical composition that comprises it, a process to obtain it and its use to treat mood disorders, Parkinson's disease and Parkinsonian disorders, gastrointestinal disorders, among others.
COMPOUNDS DERIVED FROM BENZIMIDAZOL; PREPARATION PROCESS; PHARMACEUTICAL COMPOSITION; PHARMACEUTICAL COMPOSITION PREPARATION PROCESS; AND USE IN THE TREATMENT OF A DISEASE MEDIATED BY THE ACTIVITY OF THE CANNABINOID 2 RECEIVER.
compounds, processes for their preparation, pharmaceutical composition comprising them, use of a compound, methods for the treatment and prophylaxis of arthritis, diabetes, eating disorders and obesity
COMPOUNDS DERIVED FROM SUBSTITUTED 4-IMIDAZOLS; PREPARATION PROCESS; MEDICINE; AND USE FOR THE DEPRESSION TREATMENT, ANXIETY DISORDERS, PSYCHOTIC DISORDERS, SCHIZOPHRENIA, PARKINSON'S DISEASE, MIGRANA, AMONG OTHERS.